当前位置: 首页 >> 检索结果
2806. What Will It Take to End HIV in the United States? : A Comprehensive, Local-Level Modeling Study.
作者: Anthony Todd Fojo.;Melissa Schnure.;Parastu Kasaie.;David W Dowdy.;Maunank Shah.
来源: Ann Intern Med. 2021年174卷11期1542-1553页
The Ending the HIV Epidemic (EHE) initiative aims to reduce incident HIV infections by 90% over a span of 10 years. The intensity of interventions needed to achieve this for local epidemics is unclear.
2807. Measuring the COVID-19 Mortality Burden in the United States : A Microsimulation Study.
作者: Julian Reif.;Hanke Heun-Johnson.;Bryan Tysinger.;Darius Lakdawalla.
来源: Ann Intern Med. 2021年174卷12期1700-1709页
Fully assessing the mortality burden of the COVID-19 pandemic requires measuring years of life lost (YLLs) and accounting for quality-of-life differences.
2808. Data: The Lifeblood of the Public Health Response to COVID-19.
In their article, Reif and colleagues contribute to our understanding of the burden of mortality due to the COVID-19 pandemic with a rigorous analysis to estimate years of life lost. The editorialist discusses the findings and why data are the lifeblood of any public health response to the pandemic.
2811. U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013-2018.
作者: Perrine Janiaud.;Telba Irony.;Estelle Russek-Cohen.;Steven N Goodman.
来源: Ann Intern Med. 2021年174卷11期1603-1611页
The U.S. Food and Drug Administration (FDA) has substantial flexibility in its approval criteria in the context of life-threatening disease and unmet therapeutic need.
2812. Population Immunity Against COVID-19 in the United States.
作者: Seyed M Moghadas.;Pratha Sah.;Affan Shoukat.;Lauren Ancel Meyers.;Alison P Galvani.
来源: Ann Intern Med. 2021年174卷11期1586-1591页
As of 28 July 2021, 60% of adults in the United States had been fully vaccinated against COVID-19, and more than 34 million cases had been reported. Given the uncertainty regarding undocumented infections, the population level of immunity against COVID-19 in the United States remains undetermined.
2816. Care of the Patient With Abnormal Liver Test Results.
Liver tests are commonly performed in primary care and may signal the presence of acute or chronic liver disease. Abnormal results are defined by standardized rather than individual laboratory thresholds and must be interpreted in the context of a patient's history and examination. The pattern and severity of liver injury may provide clues about the cause of disease and should guide diagnostic evaluation with serologic testing and liver imaging. A systematic, stepwise approach to the evaluation and management of abnormal liver test results is recommended to optimize high-value care.
2817. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis.
作者: Faizan Khan.;Tobias Tritschler.;Miriam Kimpton.;Philip S Wells.;Clive Kearon.;Jeffrey I Weitz.;Harry R Büller.;Gary E Raskob.;Walter Ageno.;Francis Couturaud.;Paolo Prandoni.;Gualtiero Palareti.;Cristina Legnani.;Paul A Kyrle.;Sabine Eichinger.;Lisbeth Eischer.;Cecilia Becattini.;Giancarlo Agnelli.;Maria Cristina Vedovati.;Geert-Jan Geersing.;Toshihiko Takada.;Benilde Cosmi.;Drahomir Aujesky.;Letizia Marconi.;Antonio Palla.;Sergio Siragusa.;Charlotte A Bradbury.;Sameer Parpia.;Ranjeeta Mallick.;Anthonie W A Lensing.;Martin Gebel.;Michael A Grosso.;Kednapa Thavorn.;Brian Hutton.;Gregoire Le Gal.;Dean A Fergusson.;Marc A Rodger.; .
来源: Ann Intern Med. 2021年174卷10期1420-1429页
The long-term risk for major bleeding in patients receiving extended (beyond the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous thromboembolism (VTE) is uncertain.
|